| Drug Name |
Ripretinib |
| Drug ID |
BADD_D02591 |
| Description |
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.[L13769]
It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] |
| Indications and Usage |
Ripretinib is indicated to treat adults diagnosed with advanced gastrointestinal stromal tumor (GIST) who have had prior therapy with at least 3 kinase inhibitors, including with [imatinib].[L13769] |
| Marketing Status |
approved |
| ATC Code |
L01EX19 |
| DrugBank ID |
DB14840
|
| KEGG ID |
D11353
|
| MeSH ID |
C000707850
|
| PubChem ID |
71584930
|
| TTD Drug ID |
D09AAK
|
| NDC Product Code |
59116-5331; 73207-101; 59116-5330; 59116-5332; 59116-5333 |
| UNII |
9XW757O13D
|
| Synonyms |
ripretinib | 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl- |
